Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial

Journal of Diabetes Investigation

Volumn 4, Issue 6, 2013, Pages 605-612

  Onishi, Yukiko ^a   Iwamoto, Yasuhiko ^b   Yoo, Soon Jib ^c   Clauson, Per ^d   Tamer, Søren C ^e   Park, Sungwoo ^f  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c The Catholic University of Korea   (South Korea)

^d Novo Nordisk Pharma Ltd   (Japan)

^e NOVO NORDISK A S   (Denmark)

^f Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Asian; Insulin degludec; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FLEXPEN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ARTICLE; ASIAN; BODY MASS; CHRONIC ASPECIFIC RESPIRATORY TRACT DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84888440169     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12102     Document Type: Article

References (38)

1. International Diabetes Federation. Diabetes Atlas. 5 edn. Brussels, 2012 update.
2. Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995; 18: 747-753.
3. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004; 53: 831-835.
4. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66(Suppl 1): S37-S43.
5. The Japan Diabetes Society. Evidence-Based Practice Guideline for the Treatment of Diabetes in Japan. Nankodo Co, Ltd, Bunkyo-ku, Tokyo, Japan, 2010 (Japanese).
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
7. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
8. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
9. Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care 2009; 32: S253-S259.
10. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45: 937-948.
11. Ford ES, Li C, Little RR, et al. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008; 31: 102-104.
12. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31: 81-86.
13. Kilpatrick ES, Das AK, Orskov C, et al. Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes. Curr Med Res Opin 2008; 24: 2651-2661.
14. Kanatsuka A, Kawai K, Hirao K, Japan Diabetes Clinical Data Management Study Group. Survey of drug therapy in type 2 diabetes mellitus (V). Combined treatment with insulin plus an oral hypoglycemic agents; clinical aspects and glycemic control (JDDM 19). J Japan Diab Soc 2010; 53: 737-744 (Japanese).
15. Nishimura E, Sørensen A, Hansen BF, et al. Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetes 2010; 59(Suppl 1): A375.
16. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
17. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 2011; 54(Suppl 1): S426.
18. Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
19. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
20. Birkeland KI, Home PD, Wendisch U, et al. Insulin Degludec in Type 1 Diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
21. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
22. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
23. Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care 2013; 36: 858-864.
24. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009; 107: 403-405.
25. International Conference on Harmonisation (ICH). ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001; 47: 199-203.
26. Lantus: European Public Assessmnt Report - Annex I: Summary of Product Characteristics. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf (accessed 16 December 2010).
27. Lindholm A, Jensen LB, Home PD, et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25: 876-882.
28. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289: 1-16.
29. Food and Drug Administration. Food and Drug Administration, Code of Federal Regulations, Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Draft Guidance. Available at: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071624.pdf. (accessed 16 December 2010).
30. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes. A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
31. Bergenstal R, Bhargava A, Jain R, et al. 200 U/mL Insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve people with type 2 diabetes. American Association of Clinical Endocrinologists 21st Annual Scientific Meeting and Clinical Congress 2012; A26.
32. Ratner R, Gough S, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175-184.
33. Nakar S, Yitzhaki G, Rosenberg R, et al. Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007; 21: 220-226.
34. Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007; 68: 10-15.
35. King P, Kong MF, Parkin H, et al. Well-being, cerebral function, and physical fatigue after nocturnal hypoglycemia in IDDM. Diabetes Care 1998; 21: 341-345.
36. Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011; 14: 665-671.
37. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008; 24: 87-92.
38. Heise T, Hövelmann U, Nosek L, et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetologia 2011; 54(Suppl 1): S425.